"An investment in knowledge pays the best interest."

ANTI-CANCER DRUGS EFFECTIVE IN THE DESTRUCTION OF CERVICAL CANCER

Theralase Technologies Inc.'s (TLT.V) patented, lead anti-cancer drug, TLD-1433, has been proven effective in the destruction of a human cervical carcinoma cell line, ME180.

The American Cancer Society's estimates for cervical cancer in the United States for 2017 are:

About 12,820 new cases of invasive cervical cancer will be diagnosed

About 4,210 women will die from cervical cancer

Cervical cancer was once one of the most common causes of cancer death for American women, but over the last 40 years, the cervical cancer death rate has gone down by more than 50%, due to the increased use of the Pap test.

In research conducted by Pavel Kaspler, Ph.D., Research Scientist, Theralase, under the direction of Arkady Mandel, MD, Ph.D., D.Sc., Chief Scientific Officer, Theralase, it has been demonstrated that cervical cancer cells (ME180) were up to 96% destroyed, at an extremely low dose of TLD-1433 (0.1 micromolar), when activated by green laser light (530 nm, 90 J/cm2)

The dark toxicity (TLD-1433, but no laser light applied) was virtually negligible, supporting a high safety margin in the destruction of cervical cancer cells.

To view the graphic in its original size, please click here

Dr. Kaspler stated that, "The research data collected strongly suggests that TLD-1433 would be effective in the destruction of cervical cancer with high safety margins. I look forward to continuing my research in this promising new cancer indication."

Dr. Mandel stated that, "I am very pleased that TLD-1433 continues to make strides forward in the destruction of oncology targets, demonstrating high efficacy in the destruction of numerous cancers preclinically. Clinically, in the first 3 patients treated at the Maximum Recommended Starting Dose, we have demonstrated safety and tolerability, pharmacokinetics (the movement and exit of the drug within tissue) and efficacy, when evaluated at 90 days post treatment for Non-Muscle Invasive Bladder Cancer. We have strong preclinical data supporting the use of Rutherrintrademark (TLD-1433 + transferrin) in the destruction of glioblastoma brain cancer and lung cancer and now TLD-1433 on its own in the destruction of cervical cancer."

Roger Dumoulin-White, President and CEO of Theralase stated that, "The Theralase licenced PDCs have proven to be very strong anti-cancer drugs in initial clinical studies for NMIBC and preclinically for glioblastoma, lung and now cervical cancer. We look forward to successfully expanding the oncological application of our platform of PDCs and the laser light systems that activate them, as we expand clinically into these new oncology targets."

About Theralase Technologies Inc.

Theralase Technologies Inc. ("Theralasetrademark" or the "Company") (TSXV: TLT) (OTCQX: TLTFF) in its Therapeutic Laser Technology ("TLT") Division designs, manufactures, markets and distributes patented super-pulsed laser technology indicated for the treatment of chronic knee pain, and in off-label use, the elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing for numerous nerve, muscle and joint conditions. Theralase's Photo Dynamic Therapy ("PDT") Division researches and develops specially designed molecules called Photo Dynamic Compounds ("PDCs"), which are able to localize to cancer cells and then when laser light activated, effectively destroy them.